The effectiveness of the use of ethylmethylhydroxypyridine of succinate in patients with cerebrovascular pathology against the background of diabetes and metabolic syndrome

Authors:
E.V. Ekusheva ^1.2 , E.V. Biryukova ³

¹ FSBI “Academy of post-sex education“ Federal Scientific and Clinical Center for Specialized Medical Assistance and Medical Technologies of the Federal Medical and Biological Agency ”, Moscow, Russia;
² FGAOU Belgorod State National Research University, Belgorod, Russia;
³ FSBEI in the Moscow State Medical and Dome University named after A.I. Evdokimova »Ministry of Health of Russia, Moscow, Russia

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2020, T. 120, No. 12

Summary:
the main risk factors for blood circulation diseases and the leading causes of mortality in the world continue to be arterial hypertension, diabetes, obesity and dyslipidemia, and the combination of these diseases significantly increases the likelihood of developing cardio and cerebrovascular pathology. Improving approaches to the diagnosis and therapy of these diseases is a priority problem of modern medicine. Currently, there is no universal drug that allows you to influence all links in the pathological process both in cerebrovascular diseases and in diabetes mellitus, and the problem of rational use of drugs in patients with co -filled pathology has not been completely resolved. The difficult clinical task is not only in the timely detection of the disease and making the correct diagnosis, but also in choosing the safest and most effective drug. A number of clinical studies showed the effectiveness of Mexidol in the treatment of this category of patients, which is determined by its complex, playotropic and multimodal mechanism of action. Key words: cerebrovascular diseases, diabetes mellitus, metabolic syndrome, antioxidants, Mexidol.